Experimental data established HMGB1 as a late mediator of lethal endotoxemia and sepsis, with a wide–over 24 h–therapeutic window, which allows for the clinical management of lethal systemic inflammatory diseases. This evidence concerns the gene HMGB1 and serum lipopolysaccharide activity.